Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.21, $0.05 better than the analyst estimate of $0.16. Revenue for the quarter came in at $54.5 million versus the consensus estimate of $57.5 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.